🚀 VC round data is live in beta, check it out!
Corcept Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Corcept Therapeutics and similar public comparables like China Medical System, Humanwell Healthcare, Anthem Biosciences, GSK India and more.
Corcept Therapeutics Overview
About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Founded
1998
HQ
Employees
730
Website
Sectors
Financials (LTM)
EV
$4B
Corcept Therapeutics Financials
Corcept Therapeutics reported last 12-month revenue of $800M and EBITDA of $133M.
In the same LTM period, Corcept Therapeutics generated $786M in gross profit, $133M in EBITDA, and $82M in net income.
Revenue (LTM)
Corcept Therapeutics P&L
In the most recent fiscal year, Corcept Therapeutics reported revenue of $761M and EBITDA of $130M.
Corcept Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $800M | XXX | $761M | XXX | XXX | XXX |
| Gross Profit | $786M | XXX | $748M | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | 98% | XXX | XXX | XXX |
| EBITDA | $133M | XXX | $130M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $82M | XXX | $100M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 13% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Corcept Therapeutics Stock Performance
Corcept Therapeutics has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Corcept Therapeutics' stock price is $41.91.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | -0.8% | XXX | XXX | XXX | $0.94 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCorcept Therapeutics Valuation Multiples
Corcept Therapeutics trades at 5.1x EV/Revenue multiple, and 30.8x EV/EBITDA.
EV / Revenue (LTM)
Corcept Therapeutics Financial Valuation Multiples
As of April 11, 2026, Corcept Therapeutics has market cap of $4B and EV of $4B.
Equity research analysts estimate Corcept Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Corcept Therapeutics has a P/E ratio of 54.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 5.1x | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBITDA | 30.8x | XXX | 31.4x | XXX | XXX | XXX |
| EV/EBIT | 85.3x | XXX | 91.3x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | 5.5x | XXX | XXX | XXX |
| P/E | 54.7x | XXX | 44.7x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 28.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Corcept Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Corcept Therapeutics Margins & Growth Rates
Corcept Therapeutics' revenue in the last 12 month grew by 19%.
Corcept Therapeutics' revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $1.0M for the same period.
Corcept Therapeutics' rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Corcept Therapeutics' rule of X is 61% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Corcept Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 61% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 33% | XXX | 33% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 92% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Corcept Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| China Medical System | XXX | XXX | XXX | XXX | XXX | XXX |
| Humanwell Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Anthem Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| Amicus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Corcept Therapeutics M&A Activity
Corcept Therapeutics acquired XXX companies to date.
Last acquisition by Corcept Therapeutics was on XXXXXXXX, XXXXX. Corcept Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Corcept Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCorcept Therapeutics Investment Activity
Corcept Therapeutics invested in XXX companies to date.
Corcept Therapeutics made its latest investment on XXXXXXXX, XXXXX. Corcept Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Corcept Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Corcept Therapeutics
| When was Corcept Therapeutics founded? | Corcept Therapeutics was founded in 1998. |
| Where is Corcept Therapeutics headquartered? | Corcept Therapeutics is headquartered in United States. |
| How many employees does Corcept Therapeutics have? | As of today, Corcept Therapeutics has over 730 employees. |
| Who is the CEO of Corcept Therapeutics? | Corcept Therapeutics' CEO is Joseph K. Belanoff. |
| Is Corcept Therapeutics publicly listed? | Yes, Corcept Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Corcept Therapeutics? | Corcept Therapeutics trades under CORT ticker. |
| When did Corcept Therapeutics go public? | Corcept Therapeutics went public in 2004. |
| Who are competitors of Corcept Therapeutics? | Corcept Therapeutics main competitors are China Medical System, Humanwell Healthcare, Anthem Biosciences, GSK India. |
| What is the current market cap of Corcept Therapeutics? | Corcept Therapeutics' current market cap is $4B. |
| What is the current revenue of Corcept Therapeutics? | Corcept Therapeutics' last 12 months revenue is $800M. |
| What is the current revenue growth of Corcept Therapeutics? | Corcept Therapeutics revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of Corcept Therapeutics? | Current revenue multiple of Corcept Therapeutics is 5.1x. |
| Is Corcept Therapeutics profitable? | Yes, Corcept Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Corcept Therapeutics? | Corcept Therapeutics' last 12 months EBITDA is $133M. |
| What is Corcept Therapeutics' EBITDA margin? | Corcept Therapeutics' last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Corcept Therapeutics? | Current EBITDA multiple of Corcept Therapeutics is 30.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.